PODESTA GROUP, INC. for MILLENNIUM PHARMACEUTICALS INC
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
340B-related issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Medicare/Medicaid MMM
Medicare coverage and reimbursement. H. Con. Res 112, Establishing the budget for the US Government for FY 2013. H.R. 6684, Spending Reduction Act of 2012. H.R. 8, American Taxpayer Relief Act of 2012.
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Pharmacy PHA
Prescription Drug User Fee Act reauthorization. Product exclusivity issues; pedigree issues. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act. S. 2292, Patients' FDA Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| THOMAS B SPARKMAN | — |
Budget/Appropriations BUD
H. Con. Res. 112, Establishing the budget for the US Government for FY 2013. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolution, 2013.
Foreign entity interest: Takeda Pharmaceuticals Co. Ltd. to the degree that public policies, either laws or regulations, commcercially benefit Millennium: The Takeda Oncology Company, so too Takeda Pharmaceuticals Co. Ltd., as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.